Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial

Anteris Technologies Global Corp. has reported the successful treatment of the first patients in the U.S. as part of the global pivotal PARADIGM Trial, evaluating the DurAVR® Transcatheter Heart Valve for severe calcific aortic stenosis. The trial aims to assess the safety and effectiveness of the DurAVR® THV compared to existing transcatheter aortic valve replacements. Conducted by Dr. Azeem Latib at Montefiore Medical Center, this milestone is pivotal in advancing research on heart health solutions.